The Hemoglobinopathies analysis market is projected to grow at a rate of 10.2% in terms of value, from USD 5.84 Billion in 2019 to reach USD 15.05 Billion by 2030. Hemoglobinopathies are an inherited or genetic defect that shows the abnormal structure of the globin chains (hbb gene sequencing) of the hemoglobin molecule.
The market is observing high growth due to growing incidences of sickle cell disease (SCD), thalassemia (both alpha and beta types), hemoglobin C disease, and hemoglobin S-C disease, among others, and the increasing need for the treatment of the diseases. These are a diverse set of congenital blood ailments that are a consequence of disparities in the structure and synthesis of hemoglobin. It is a genetic disorder of which Sickle cell is most common. Several pharmaceutical companies such as LabCorp and Quest Diagnostics are involved in the diagnosis and evaluation of Hemoglobinopathies.
The hemoglobinopathies represent every single hereditary infection of hemoglobin. They fall into two fundamental gatherings: thalassemia disorders and basic hemoglobin variations (anomalous hemoglobins). α-and β-thalassemia is the fundamental sorts of thalassemia; the principle auxiliary hemoglobin variations are HbS, HbE, and HbC. There are numerous subtypes and consolidated sorts in each gathering. Hemoglobinopathies are a general medical problem in the present multiethnic populace in the developed world. With roughly 7% of the overall populace being transporters, hemoglobinopathies are the most widely recognized monogenic infections and one of the world’s significant medical issues. They were initially found chiefly in the Mediterranean region and enormous parts of Asia and Africa. Worldwide migration has spread them from those zones everywhere throughout almost all nationalities. In numerous parts of Europe today, hemoglobin (Hb) defects are delegated endemic diseases. Hemoglobinopathy analysis in routine practice includes a red platelet (RBC) tally with erythrocyte indices, and a hemoglobin test (hemoglobin electrophoresis and chromatography). Specialized tests in facilities qualified for the purpose are often required. Adequate consideration of the influenced patients requires a wide assortment of symptomatic and diagnostic estimates.
Request a Sample@ https://qyresearchmedical.com/sample/118993
The highly variable clinical indications of the hemoglobinopathies run from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Stem-cell transplantation is the favored treatment for the serious types of thalassemia. Strong, as opposed to remedial, treatment comprises of occasional blood transfusions for a lifetime, joined with iron chelation. Medications to treat the side effects of sickle-cell illness incorporate analgesics, anti-microbials, ACE inhibitors, and hydroxyurea. Blood transfusions ought to be given just when carefully showed. Over 90% of patients right now get by into adulthood. Ideally, treated patients have an anticipated life expectancy of 50 to 60 years. The development of Hemoglobinopathies market is driven by the developing of hemoglobinopathies in developed countries, high ailment events in developing countries, different government healthcare expenditures, and non-government subsidizing of medication and treatment. Different factors which are boosting this hemoglobinopathies market are diagnostics and therapeutics, good repayment situation for indicative tests and treatment, a financially sound preventive methodology like hereditary testing, and advancement of fast purpose of-care analytic techniques.
The worldwide hemoglobinopathies market is circulated into five significant regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. As indicated by the World Health Organization, around 300,000 to 500,000 children born every year are influenced by hemoglobin issue. The absence of awareness measures about this disease may prompt the demise of a patient experiencing sickle cell and thalassemia. Lack of awareness regarding hemoglobinopathy disorders amongst the population, especially in underdeveloped countries and lack of high sensitivity and specific diagnostic tests, are expected to restraint the market growth to a certain extent. Conversely, the untapped potential of emerging economies is anticipated to provide lucrative growth opportunities to the market players involved in the Hemoglobinopathies market during the forecast period.
However, ambiguity in the regulatory framework and cost-prohibitive protein analysis equipment may create hindrances in the growth of the market in the forecast period
Thalassemia segment was valued as the highest growing segment in 2019 and is expected to grow at an appreciable CAGR from 2020-2030. Thalassemia is a kind of genetic blood disorder that leads to a decrease in the production of hemoglobin in the human body. Symptoms of the disease comprise weakness, fatigue, facial bone deformities, pale or yellowish skin, abdominal swelling, slow growth, and dark urine. Some infants show symptoms of the disease at birth, whereas others develop the signs during the initial two years of life.
Therapy Type Outlook:
Blood transfusion therapy is a significant method for managing patients with sickle cell disease and thalassemia. Blood transfusion in sickle cell disease patients may be for severe indications, and in such cases, this therapy can prove life-saving. These symptoms range from the individuals in which transfusion is highly recommended to the individuals where the results are uncertain, and thus needing a personalized decision. The purpose of blood transfusion therapy is to improve the quality of life by improving anemia and subduing ineffective erythropoiesis, at the same time, lessening the difficulties of the transfusion.
Test Type Outlook:
The market for the red blood cell counts test segment is the highest in the Test segment and is expected to show appreciable growth during the forecast period. Hemoglobinopathies are genetic disorders that influence the count/shape of the red blood cells in the human body. Mild cases of hemoglobinopathies may need no medical treatment, whereas severe cases may be left untreated, and result in red blood cell shortage or even death.
A red blood cell count or erythrocyte count is deployed to ascertain how many red blood cells (RBCs) are present in the human body. The test is essential as RBCs comprise hemoglobin that transports oxygen to the bodily tissues, which require oxygen for their proper functioning.
The Genetic testing sub-segment clocked in a CAGR of 8.2% during the forecast period.
Asia-Pacific regional segment of the Hemoglobinopathies market is expected to remain highest growing segment during 2020-2030, at a CAGR of 9.0%, Untapped market potential is offered by hemoglobinopathies in developing nations such as China, India, Vietnam, and The Philippines
North America leads the overall hemoglobinopathies market in terms of revenue in 2018 with a significant market share and is expected to retain this position till 2026.
- The global hemoglobinopathies market has moderately concentrated, and the market is in a growth phase; the competition among companies is more.
- The main growth factors of hemoglobinopathies market are increasing the prevalence of hemoglobinopathies in developed countries, high-level diseases, a variety of government support initiatives, and an increase in NGO funding.
- Due to an increase in sickle cell diseases and a strong product pipeline such as LentiGlobin, SCD segments accounted for the largest market share in 2019.
- Some of the drugs such as NiCord, ZFP Transcription Factors, ALN-TMP, Drug Targeting PRMT5, and others are used for hemoglobinopathies treatment. An increase in drug development is anticipated to boost the market.
- Common therapies available for treatment are blood transfusion, bone marrow transplant, chelation therapy, and hydroxyurea, but higher capital & reagent costs and inadequate required skills and experience for interpreting the results due to data complexity are some reasons that will prove to be obstacles for the hemoglobinopathies market growth.
Key participants include Alnylam Pharmaceuticals, Gamida Cell, Biogen Idec, AcceleronPharma, Sangamo BioSciences, Anthera Pharmaceuticals, Global Blood Therapeutics, Geetix Pharmaceuticals, Mast Therapeutics, Prolong Pharmaceuticals, Emmaus Medical, Celgene Corporation, Invenux, Optinova Ab, and HemaQuest Pharmaceuticals.
The players operating in the market have undertaken a number of strategies related to the market in the period 2019-2020. Some of the key highlights are:
- In February 2019, Biogen Inc. made an announcement about the conclusion of the separation of its hemophilia business. The Bioverativ, the newly formed biotechnological entity, is emphasized on rare blood disorders.
The industry offers numerous growth opportunities. Thus, a number of startups providing innovative products and technologies have been entering the market. Some of them include GBT, Imara, Pharming Group, LogicBio Therapeutics, and Modus Therapeutics, among others.
Mergers and Acquisitions are an integral part of the industry. Along with the companies operating in the market, other key market players have also been entering the industry.
- In August 2019, CSL Behring made an announcement about its decision to acquire Calimmune, Inc. for an advance payment of USD 91.0 million.
Reports and Data forecasts promising developments for increased adoption of Hemoglobinopathies. According to industry experts, the use of bone marrow transplant is garnering significant traction in the market. New companies entering the industry would emphasize designing and developing innovative products, thereby catering to the increasing requirement of end-users.
Segments covered in the report:
This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the industry trends in each of the sub-segments from 2019 to 2030. The scope of the report can be defined as:
For the purpose of this study, Reports and Data have segmented the Hemoglobinopathies market on the basis of type, therapy type, test type, and region:
Type Outlook (Revenue, USD Million; 2019-2030)
- Alpha Thalassemia
- Beta Thalassemia
- Sickle Cell Disease
- Other Hb Variants Diseases
Therapy Type Outlook (Revenue, USD Million; 2019-2030)
- Blood transfusion
- Iron chelation therapy
- Bone marrow transplant
Test Type Outlook (Revenue, USD Million; 2019-2030)
- Red blood cell (RBC) count test
- Genetic testing
- Liquid chromatography (HPLC) test
- Hemoglobin isoelectric (Hb IEF) focusing
- Hemoglobin electrophoresis (Hb ELP) test
- Hemoglobin solubility test
Regional Outlook (Revenue, USD Million; 2019-2030)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Saudi Arabia
- Rest of the Middle East and Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118993/1500
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: